Annette Hay
Annette Hay
Associate Professor, Queen's University
Bestätigte E-Mail-Adresse bei - Startseite
Zitiert von
Zitiert von
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, J Westin, ...
Blood, The Journal of the American Society of Hematology 130 (16), 1800-1808, 2017
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for …
M Crump, J Kuruvilla, S Couban, DA MacDonald, V Kukreti, CT Kouroukis, ...
Journal of Clinical Oncology 32 (31), 3490-3496, 2014
CAR T-cells: costs, comparisons, and commentary
AE Hay, MC Cheung
Journal of Medical Economics 22 (7), 613-615, 2019
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12
J Kuruvilla, DA MacDonald, CT Kouroukis, M Cheung, HJ Olney, ...
Blood, The Journal of the American Society of Hematology 126 (6), 733-738, 2015
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma
AE Hay, B Klimm, BE Chen, H Goergen, LE Shepherd, M Fuchs, ...
Annals of oncology 24 (12), 3065-3069, 2013
Consensus guidelines on the diagnosis of multiple myeloma and related disorders: recommendations of the myeloma Canada research network consensus guideline consortium
DJ Bergstrom, R Kotb, ML Louzada, HJ Sutherland, S Tavoularis, ...
Clinical Lymphoma Myeloma and Leukemia 20 (7), e352-e367, 2020
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group
MD Seftel, J Kuruvilla, T Kouroukis, V Banerji, G Fraser, M Crump, ...
Leukemia & lymphoma 58 (6), 1358-1365, 2017
A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND. 191
AE Hay, A Murugesan, AM DiPasquale, T Kouroukis, I Sandhu, V Kukreti, ...
Leukemia & lymphoma 57 (6), 1463-1466, 2016
The economic impact of the transition from branded to generic oncology drugs
WY Cheung, EA Kornelsen, N Mittmann, NB Leighl, M Cheung, KK Chan, ...
Current Oncology 26 (2), 89-93, 2019
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY. 12 randomized phase 3 study
T Skamene, M Crump, KJ Savage, T Reiman, J Kuruvilla, D Good, ...
Leukemia & Lymphoma 58 (10), 2319-2327, 2017
Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to …
K Davison, BE Chen, V Kukreti, S Couban, A Benger, NL Berinstein, ...
Annals of Oncology 28 (3), 622-627, 2017
Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada
PA Tang, AE Hay, CJ O’Callaghan, N Mittmann, CR Chambers, JL Pater, ...
Current Oncology 23 (s1), 7-13, 2016
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome
JG Monzon, AE Hay, GT McDonald, JL Pater, RM Meyer, E Chen, ...
European Journal of Cancer 51 (17), 2501-2507, 2015
Accrual of adolescents and young adults with cancer to clinical trials
AE Hay, C Rae, GA Fraser, RM Meyer, LS Abbott, S Bevan, ML McBride, ...
Current Oncology 23 (2), e81, 2016
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the …
T Reiman, KJ Savage, M Crump, MC Cheung, D MacDonald, R Buckstein, ...
Leukemia & Lymphoma 60 (4), 912-919, 2019
Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.
M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, ...
Journal of Clinical Oncology 34 (15_suppl), 7516-7516, 2016
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry
JPS Sawhney, VA Kothiwale, V Bisne, R Durgaprasad, P Jadhav, ...
Indian heart journal 70 (6), 828-835, 2018
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY. 12
MC Cheung, AE Hay, M Crump, KR Imrie, Y Song, S Hassan, ...
Journal of the National Cancer Institute 107 (7), djv106, 2015
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia
RB Walter, LC Michaelis, M Othus, GL Uy, JP Radich, RF Little, S Hita, ...
American journal of hematology 93 (2), E49, 2018
Linkage of clinical trial and administrative data: a survey of cancer patient preferences
AE Hay, YW Leung, JL Pater, MC Brown, E Bell, D Howell, Z Kassam, ...
Current Oncology 24 (3), 161-167, 2017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20